natgillin/translations-raw huggingface dataset:
Eviplera contains an NNRTI (rilpivirine) and so Eviplera is not to be combined with other medicines of this type. 
Zdravilo Eviplera vsebuje NNRTI (rilpivirin), zato se zdravila Eviplera ne sme kombinirati z drugimi zdravili te vrste.
No other pathways of resistance to emtricitabine or tenofovir have been identified. 
Drugih poti razvoja rezistence na emtricitabin ali tenofovir niso ugotovili.
Do not give this medicine to children and adolescents under 18 years of age. 
Otrokom in mladostnikom, starim pod 18 let, ne dajajte tega zdravila.
In other studies (prospective and cross-sectional), the most pronounced decreases in BMD were seen in patients treated with tenofovir disoproxil as part of a regimen containing a boosted protease inhibitor (PI). 
V drugih študijah (prospektivne in presečne) so najbolj izrazito zmanjšanje MGK opazili pri bolnikih, zdravljenih z dizoproksiltenofoviratom kot del režima, ki je vseboval okrepljenega zaviralca proteaze (PI, protease inhibitor).
Your doctor may consider giving you the components of Eviplera separately if you are having problems or need your dose adjusted. 
Vaš zdravnik vam bo morda učinkovine zdravila Eviplera predpisal ločeno, če imate težave ali je treba odmerek prilagoditi.
The K103N substitution alone did not result in reduced susceptibility to rilpivirine, but the combination of K103N and L100I resulted in a 7-fold reduced susceptibility to rilpivirine. 
Samo substitucija K103N ni povzročila manjše občutljivosti na rilpivirin, vendar pa je kombinacija K103N in L100I povzročila 7-krat manjšo občutljivost na rilpivirin.
The safety profile of emtricitabine and tenofovir disoproxil in these studies was consistent with the previous experience with these agents when each was administered with other antiretroviral agents. 
Varnostni profil emtricitabina in dizoproksiltenofovirata v teh študijah je bil skladen s predhodnimi izkušnjami s tema učinkovinama, ko so bolniki vsako od njiju prejemali z drugimi protiretrovirusnimi zdravili.
Each of these active substances, also known as antiretroviral medicines, works by interfering with an enzyme (a protein called ‘reverse transcriptase') that is essential for the virus to multiply. 
Vsaka od teh učinkovin, znanih kot protiretrovirusna zdravila, deluje tako, da vpliva na encim (na beljakovino, imenovano ‘reverzna transkriptaza'), ki je nujen za razmnoževanje virusa.
However, in some patients, declines in CrCl did not completely resolve despite tenofovir disoproxil discontinuation. 
Vendar pa pri nekaterih bolnikih upad CrCl ni povsem izzvenel, kljub prekinitvi dizoproksiltenofovirata.
• Pain, stomach pain or discomfort, feeling bloated, dry mouth 
• bolečina, bolečine ali nelagodje v trebuhu, občutek napihnjenosti, suha usta
While taking Eviplera you may still develop infections or other illnesses associated with HIV infection. 
Kljub jemanju zdravila Eviplera se lahko pojavijo okužbe ali druge bolezni, povezane z okužbo z virusom HIV.
Some patients have had blood tests or symptoms indicating that their hepatitis has got worse after stopping emtricitabine or tenofovir disoproxil (two of the three active substances of Eviplera). 
Krvne preiskave ali simptomi pri nekaterih bolnikih so kazali, da se je njihov hepatitis poslabšal po prenehanju zdravljenja z emtricitabinom ali dizoproksiltenofoviratom (dve od treh učinkovin zdravila Eviplera).
Dosing recommendations for paediatric patients cannot be made due to insufficient data (see section 4.2). 
Priporočil o odmerjanju za pediatrično populacijo ni mogoče dati zaradi nezadostnih podatkov (glejte poglavje 4.2).
Table 1: Interactions between Eviplera or its individual component(s) and other medicinal products 
Preglednica 1: Interakcije med zdravilom Eviplera ali njegovo(-imi) posamično(-imi) učinkovino(-ami) in drugimi zdravili
The K65R, M184V, and K65R+M184V mutants of HIV-1 remain fully susceptible to rilpivirine. 
Mutanti K65R, M184V in K65R+M184V virusa HIV-1 ostajajo povsem občutljivi na rilpivirin.
The single resistance-associated mutations associated with a loss of susceptibility to rilpivirine were: K101P and Y181V/I. 
Edini mutaciji, povezani z rezistenco, ki sta bili povezani z izgubo občutljivosti na rilpivirin, sta bili: K101P in Y181V/I.
d Includes patients who discontinued due to AE or death at any time point from day 1 through the week 24 window resulting in no virologic data on treatment during the specified window. 
d Vključuje bolnike, ki so prenehali sodelovati zaradi neželenih učinkov ali smrti, kadar koli od 1. dne do konca časovnega okna 24. tedna, če zaradi tega v določenem oknu ni bilo viroloških podatkov o zdravljenju.
No dose adjustment is recommended. 
Prilagoditev odmerka se ne priporoča.
Patients had to have previously only received efavirenz/emtricitabine/tenofovir disoproxil as their first antiretroviral regimen for at least three months, and wished to switch regimens due to efavirenz intolerance. 
Bolniki so morali predhodno vsaj tri mesece prejemati le efavirenz/emtricitabin/dizoproksiltenofovirat kot svoj prvi protiretrovirusni režim za vsaj tri mesece in so želeli preiti na drug režim zaradi neprenašanja efavirenza.
Ethnicity No clinically important pharmacokinetic differences due to ethnicity have been identified. 
Etnična pripadnost Klinično pomembnih farmakokinetičnih razlik glede na etnično pripadnost niso ugotovili.
It is recommended that CrCl is calculated in all patients prior to initiating therapy with Eviplera and renal function (CrCl and serum phosphate) is also monitored after two to four weeks of treatment, after three months of treatment and every three to six months thereafter in patients without renal risk factors. 
Pred začetkom zdravljenja z zdravilom Eviplera se priporoča izračun CrCl pri vseh bolnikih in nadzor delovanja ledvic (CrCl in vrednost serumskega fosfata) po dveh do štirih tednih zdravljenja, po treh mesecih zdravljenja in zatem vsake tri do šest mesecev pri bolnikih brez dejavnikov tveganja za ledvice.
Any signs of inflammation or infection. 
Vsakršni znak vnetja ali okužbe.
• Tell your doctor if you have an allergy to sunset yellow aluminium lake (E110). 
• Obvestite zdravnika, če imate alergijo na barvilo sončno rumeno FCF (E110).
• If you are allergic to emtricitabine, rilpivirine, tenofovir disoproxil, or any of the other ingredients of this medicine (listed in section 6 of this leaflet). 
• Če ste alergični na emtricitabin, rilpivirin, dizoproksiltenofovirat ali na katero koli sestavino tega zdravila (navedeno v poglavju 6 tega navodila).
At a dose of 25 mg of rilpivirine, no dose adjustment is required. 
Pri odmerku 25 mg rilpivirina odmerka ni treba prilagajati.
hypertriglyceridaemia1, 2, hyperglycaemia1, decreased appetite2 
hipertrigliceridemija1, 2, hiperglikemija1, zmanjšanje apetita2
Eviplera must be taken orally, once daily with food (see section 5.2). 
Zdravilo Eviplera se mora jemati peroralno, enkrat dnevno s hrano (glejte poglavje 5.2).
In the Phase III studies (C209 and C215), lower rilpivirine exposure, similar to that seen during pregnancy, has been associated with an increased risk of virological failure, therefore viral load should be monitored closely (see sections 4.6, 5.1 and 5.2). 
V študijah faze III (C209 in C215) je bila nižja izpostavljenost rilpivirinu, podobna kot je bila opažena med nosečnostjo, povezana s povečanim tveganjem za virološki neuspeh, zato je treba skrbno spremljati virusno obremenitev (glejte poglavja 4.6, 5.1 in 5.2).
Emtricitabine triphosphate and tenofovir diphosphate competitively inhibit HIV-1 RT, resulting in DNA chain termination. 
Emtricitabin trifosfat in tenofovir difosfat kompetitivno inhibirata RT HIV-1, kar rezultira v prekinitvi verige DNA.
Eviplera may interact with other medicines. 
Zdravilo Eviplera lahko medsebojno deluje z drugimi zdravili.
• Women must not get pregnant while taking Eviplera. 
• Ženske ne smejo zanositi, medtem ko se zdravijo z zdravilom Eviplera.
• Joint aches and pains (especially of the hip, knee and shoulder) 
• bolečine (zlasti v kolkih, kolenih in ramenih)
Study GS-US-264-0106 
Študija GS-US-264-0106
DXA substudies showed that small but statistically significant decreases from baseline in whole body BMD and BMC were similar for rilpivirine and control at week 48 and week 96. 
Podštudije z DXA so pokazale, da so bila majhna, a statistično značilna zmanjšanja od začetne vrednosti BMD in BMC celega telesa podobna za rilpivirin in kontrolno skupino v 48. in 96. tednu.
• Breakdown of muscle, muscle pain or weakness 
• razpad mišičnega tkiva, bolečine v mišicah ali mišična oslabelost
Since emtricitabine and tenofovir are primarily eliminated by the kidneys, co-administration of Eviplera with medicinal products that reduce renal function or compete for active tubular secretion (e.g. cidofovir) may increase serum concentrations of emtricitabine, tenofovir and/or the co-administered medicinal products. 
Ker se emtricitabin in tenofovir izločata predvsem preko ledvic, sočasna uporaba zdravila Eviplera in zdravil, ki zmanjšujejo delovanje ledvic ali tekmujejo za aktivno tubularno sekrecijo (npr. cidofovir), lahko poveča serumske koncentracije emtricitabina, tenofovirja in/ali sočasno uporabljenih zdravil.
The dosing recommendation is applicable to the recommended dose of rilpivirine of 25 mg once daily. 
Priporočilo za odmerjanje velja za priporočen odmerek rilpivirina 25 mg enkrat dnevno.
The administration of Eviplera to healthy adult subjects with either a light meal (390 kcal) or a standard meal (540 kcal) resulted in increased exposures of rilpivirine and tenofovir relative to fasting conditions. 
Dajanje zdravila Eviplera zdravim odraslim osebam z lahkim obrokom (390 kcal) ali standardnim obrokom (540 kcal) je povzročila večjo izpostavljenost rilpivirinu in tenofovirju v primerjavi z izpostavljenostjo na tešče.
HIV-1 RNA < 50 copies/mL 
HIV-1 RNA < 50 kopij/ml
No mother to child transmission occurred in all 10 infants born to the mothers who completed the study and for whom the HIV status was available. 
Pri nobenem od 10 novorojencev, ki so se rodili materam, ki so zaključile študijo in pri katerih je bil na voljo podatek glede HIV statusa, ni prišlo do prenosa z matere na otroka.
The film-coated tablet should not be chewed, crushed or split as it may impact the absorption of Eviplera. 
Filmsko obložene tablete ni dovoljeno žvečiti, zdrobiti ali razpoloviti, saj lahko to vpliva na absorpcijo zdravila Eviplera.
If you forget to take Eviplera 
Če ste pozabili vzeti zdravilo Eviplera
• If you notice within 12 hours of the time you usually take Eviplera, you must take the tablet as soon as possible. 
• Če opazite v roku 12 ur od časa, ko zdravilo Eviplera običajno vzamete, morate tableto vzeti čim prej.
What you need to know before you take Eviplera Do not take Eviplera 
Kaj morate vedeti, preden boste vzeli zdravilo Eviplera Ne jemljite zdravila Eviplera
Study GS-US-264-0111 
Študija GS-US-264-0111
proximal renal tubulopathy including Fanconi syndrome3, increased creatinine3, proteinuria3 
proksimalna ledvična tubulopatija, vključujoč Fanconijev sindrom3, povišan kreatinin3, proteinurija3
A subgroup of patients with baseline CrCl between 50 and 60 mL/min, receiving once daily dosing, had a 2- to 4-fold increase in tenofovir exposure and worsening renal function. 
Podskupina bolnikov z začetno vrednostjo CrCl med 50 in 60 ml/min, ki so ji zdravilo odmerjali enkrat dnevno, je imela 2 do 4-kratno povečanje izpostavljenosti tenofovirju in poslabšanje delovanja ledvic.
Eviplera has not been evaluated in patients with previous virologic failure to any other antiretroviral therapy. 
Zdravila Eviplera niso ovrednotili pri bolnikih s predhodnim virološkim neuspehom na drugo protiretrovirusno zdravljenje.
If you have hepatitis B infection, liver problems may become worse after you stop taking Eviplera. 
Če imate okužbo s hepatitisom B, se lahko težave z jetri poslabšajo, ko prenehate jemati zdravilo Eviplera.
renal failure (acute and chronic)3, acute tubular necrosis3, nephritis (including acute interstitial nephritis)3, 8, nephrogenic diabetes insipidus3 
ledvična odpoved (akutna in kronična)3, akutna tubularna nekroza3, nefritis (vključno z akutnim intersticijskim nefritisom)3, 8, nefrogeni insipidusni diabetes3
In study C209 (n = 690), the BR was emtricitabine/tenofovir disoproxil. 
V študiji C209 (n = 690), je bil BR emtricitabin/dizoproksiltenofovirat.
Of the 26 patients without data available in the week 48 window, 7 patients discontinued due to adverse event (AE) or death, 16 patients discontinued for other reasons, and 3 patients were missing data but remained on study drug. 
Med 26 bolniki, ki v oknu 48. tedna niso imeli razpoložljivih podatkov, se je 7 bolnikov prenehalo zdraviti zaradi neželenega učinka ali smrti, 16 bolnikov se je prenehalo zdraviti zaradi drugih razlogov, pri 3 bolnikih pa ni bilo podatkov, vendar so se še naprej zdravili s študijskim zdravilom.
Following intravenous administration the volume of distribution of the single components emtricitabine and tenofovir was approximately 1,400 mL/kg and 800 mL/kg, respectively. 
Po intravenskem odmerku je volumen porazdelitve posameznih sestavin emtricitabina znašal približno 1,400 ml/kg in volumen porazdelitve tenofovirja približno 800 ml/kg.
 If you notice any symptoms of inflammation or infection, tell your doctor immediately. 
 Če opazite kakršne koli simptome vnetja ali okužbe, takoj obvestite zdravnika.
Take the rilpivirine tablet at the same time you take Eviplera. 
Tableto rilpivirina vzemite sočasno z zdravilom Eviplera.
In vitro binding of emtricitabine to human plasma proteins was < 4% and independent of concentration over the range of 0.02 to 200 µg/mL. 
In vitro je bila vezava emtricitabina na humane plazemske proteine manj kot < 4 % in je neodvisna od koncentracije v razponu med 0,02 in 200 µg/ml.
Other medicines and Eviplera Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. 
Obvestite zdravnika ali farmacevta, če jemljete, ste pred kratkim jemali ali pa boste morda začeli jemati katero koli drugo zdravilo.
Following oral administration of tenofovir disoproxil to HIV infected patients, tenofovir disoproxil is rapidly absorbed and converted to tenofovir. 
Po peroralnem dajanju dizoproksiltenofovirata bolnikom, okuženim z virusom HIV, se dizoproksiltenofovirat hitro absorbira in pretvori v tenofovir.
Rilpivirine hydrochloride is primarily metabolised and eliminated by the liver. 
Rilpivirinijev klorid se pretežno presnavlja in izloča z jetri.
In patients with severe renal impairment or ESRD, plasma concentrations may be increased due to alteration of drug absorption, distribution and/or metabolism secondary to renal dysfunction. 
Pri bolnikih s hudo ledvično okvaro ali z ESRD so lahko koncentracije v plazmi povišane zaradi spremenjene absorpcije, porazdelitve in/ali presnove zdravila kot posledica ledvične disfunkcije.
(≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100) or rare (≥ 1/10,000 to < 1/1,000). 
Pogostnost je definirana kot zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1.000 do < 1/100) ali redki neželeni učinki (≥ 1/10.000 do < 1/1.000).
Eviplera comes in bottles of 30 tablets and in packs made up of 3 bottles, each containing 30 tablets. 
Zdravilo Eviplera je na voljo v plastenkah po 30 tablet in v pakiranjih s po 3 plastenkami, od katerih vsaka vsebuje 30 tablet.
Findings in repeated dose toxicity studies in rats, dogs and monkeys at exposure levels greater than or equal to clinical exposure levels and with possible relevance to clinical use included kidney and bone changes and a decrease in serum phosphate concentration. 
Izsledki iz študij toksičnosti pri ponavljajočih odmerkih pri podganah, psih in opicah pri stopnjah izpostavljenosti, ki so bile večje ali enake stopnjam klinične izpostavljenosti, in ki so morda pomembne za klinično uporabo, vključujejo spremembe ledvic in kosti in zmanjšanje koncentracije serumskega fosfata.
In faeces, unchanged rilpivirine accounted for on average 25% of the administered dose. 
V blatu je bil delež nespremenjenega rilpivirina povprečno 25 % danega odmerka.
Interactions between Eviplera or its individual component(s) and co-administered medicinal products are listed in Table 1 below (increase is indicated as “↑”, decrease as “↓” and no change as “↔”). 
Interakcije med zdravilom Eviplera ali njegovo(-imi) posamično(-imi) učinkovino(-ami) sočasno uporabljenimi zdravili so navedene v preglednici 1 spodaj (povečanje je označeno z znakom “↑”, zmanjšanje z “↓” in brez spremembe z “↔”).
If concomitant use of Eviplera and nephrotoxic agents is unavoidable, renal function must be monitored weekly (see sections 4.5 and 4.8). 
Če je sočasna uporaba zdravila Eviplera in nefrotoksičnega zdravila neizogibna, je treba tedensko nadzorovati ledvično funkcijo (glejte poglavji 4.5 in 4.8).
The remaining 3 Eviplera-treated patients did not have emergent resistance. 
Preostali 3 bolniki, zdravljeni z zdravilom Eviplera, niso imeli rezistence, nastale med zdravljenjem.
c Includes patients who had HIV-1 RNA ≥ 50 copies/mL in the week 24 window, patients who discontinued early due to lack or loss of efficacy, patients who discontinued for reasons other than an adverse event (AE) or death, and at the time of discontinuation had a viral value of ≥ 50 copies/mL. 
c Vključuje bolnike, ki so imeli v oknu 24. tedna HIV-1 RNA ≥ 50 kopij/ml, bolnike, ki so predčasno prekinili sodelovanje zaradi pomanjkanja ali izgube učinka, bolnike, ki so sodelovanje prekinili zaradi drugih razlogov, kot so neželeni učinki, smrt ali pomanjkanje oz. izguba učinka, in so imeli v času prekinitve virološko vrednost ≥ 50 kopij/ml.
Patients were randomised in a 1:1 ratio to receive either rilpivirine hydrochloride 25 mg (n = 686) once daily or efavirenz 600 mg (n = 682) once daily in addition to a BR. 
Bolniki so bili randomizirani v razmerju 1:1 za prejemanje bodisi rilpivirinijevega klorida 25 mg (n = 686) enkrat dnevno ali efavirenza 600 mg (n = 682) enkrat dnevno kot dodatek k BR.
Rilpivirine does not inhibit the human cellular DNA polymerases α, β and mitochondrial DNA polymerase γ. 
Rilpivirin ne zavira humanih celičnih DNA polimeraz α, β in mitohondrijske DNA polimeraze γ.
In a panel of 67 HIV-1 recombinant laboratory strains with one resistance-associated mutation at RT positions associated with NNRTI resistance, including the most commonly found K103N and Y181C, rilpivirine showed antiviral activity against 64 (96%) of these strains. 
V naboru 67 rekombinantnih laboratorijskih sevov virusa HIV-1 z eno mutacijo, povezano z rezistenco, na položajih RT, povezanih z rezistenco na NNRTI, vključno z najpogosteje najdenima K103N in Y181C, je rilpivirin pokazal protiretrovirusno aktivnost proti 64 (96 %) teh sevov.
Since Eviplera is a combination product and the dosing interval of the individual components cannot be altered, treatment with Eviplera must be interrupted in patients with confirmed CrCl decreased to < 50 mL/min or decreases in serum phosphate to < 1.0 mg/dL (0.32 mmol/L). 
Ker je zdravilo Eviplera kombinirano zdravilo in intervala odmerjanja posameznih sestavin ni mogoče spreminjati, je treba zdravljenje z zdravilom Eviplera pri bolnikih s potrjenim zmanjšanjem CrCl na < 50 ml/min ali zmanjšanjem serumskega fosfata na < 1,0 mg/dl (0,32 mmol/l) prekiniti.
Some patients taking combination antiretroviral medicines such as Eviplera may develop a bone disease called osteonecrosis (death of bone tissue caused by loss of blood supply to the bone). 
Pri nekaterih bolnikih, ki jemljejo kombinirana protiretrovirusna zdravila, kot je zdravilo Eviplera, se lahko pojavi bolezen kosti, imenovana osteonekroza (odmiranje kostnega tkiva kot posledica pomanjkanja oskrbe kosti s krvjo).
• aminoglycosides (such as streptomycin, neomycin and gentamicin), vancomycin (for bacterial infections) 
• aminoglikozidi (kot so streptomicin, neomicin in gentamicin), vankomicin (za bakterijske okužbe)
Following oral administration of Eviplera with food emtricitabine is rapidly and extensively absorbed with maximum plasma concentrations occurring within 2.5 hours post-dose. 
Po peroralnem vnosu zdravila Eviplera s hrano se emtricitabin hitro in znatno absorbira, pri čemer so koncentracije v plazmi najvišje 2,5 ure po odmerku.
As soon as serious skin and/or mucosal reactions are observed, Eviplera must be discontinued and appropriate therapy should be initiated. 
Takoj po pojavu resnih kožnih in/ali sluzničnih reakcij je treba zdravljenje z zdravilom Eviplera prekiniti in uvesti ustrezno zdravljenje.
There were also reclassifications in the week 48 primary analysis with the most common being reclassification from virologic failure to discontinued for non-AE reasons. 
Pri primarni analizi v 48. tednu je prišlo tudi do prerazvrstitve, pri čemer je bila najpogostejša prerazvrstitev iz skupine virološkega neuspeha v skupino prekinitev, ne zaradi AE.
There were no new safety findings compared with the known safety profile of rilpivirine in HIV-1 infected adults (see sections 4.2, 4.4 and 5.2). 
V primerjavi z znanim varnostnim profilom rilpivirina pri odraslih, okuženih s HIV-1, ni bilo nobenih novih varnostnih ugotovitev (glejte poglavja 4.2, 4.4 and 5.2).
Bone toxicity was diagnosed as osteomalacia (monkeys) and reduced BMD (rats and dogs). 
Toksičen vpliv na kosti je bil diagnosticiran kot osteomalacija (pri opicah) in kot zmanjšana mineralna gostota kosti (podgane in psi).
• Inflammation of the kidney, passing a lot of urine and feeling thirsty 
• vnetje ledvic, izločanje večjih količin urina in občutek žeje
There are a limited amount of data (less than 300 pregnancy outcomes) from the use of rilpivirine in pregnant women (see sections 4.4, 5.1 and 5.2). 
Podatki o uporabi rilpivirina pri nosečnicah so omejeni (manj kot 300 izidov nosečnosti) (glejte poglavja 4.4, 5.1 in 5.2).
At week 48, 94% (46/49) of patients remained suppressed, and 4% (2/49) were considered virologic failures (HIV-1 RNA ≥ 50 copies/mL). 
V 48. tednu je supresijo ohranilo 94 % (46/49) bolnikov, 4 % (2/49) pa so bili obravnavani kot virološki neuspeh (HIV-1 RNA ≥ 50 kopij/ml).
Rilpivirine is a diarylpyrimidine NNRTI of HIV-1. 
Rilpivirin je diarilpirimidin NNRTI HIV-1.
b Snapshot analysis. 
b Analiza posnetka stanja.
One patient (2%) did not have data available in the week 48 window; study drug was discontinued due to a protocol violation (i.e. reason other than AE or death) and the last available HIV-1 RNA was < 50 copies/mL. 
Za enega bolnika (2 %) v oknu 48. tedna ni bilo na voljo podatkov; študijsko zdravilo so ukinili zaradi kršitve protokola (tj. drugi razlogi, kot so neželeni učinki ali smrt) in nazadnja razpoložljiva vrednost HIV-1 RNA je bila < 50 kopij/ml.
Rilpivirine inhibits P-glycoprotein (P-gp) in vitro (IC50 is 9.2 µM). 
Rilpivirin in vitro zavira P-glikoprotein (P-gp) (IC50 je 9,2 µM).
Eviplera contains lactose monohydrate. 
Zdravilo Eviplera vsebuje laktozo monohidrat.
• Abnormal dreams, sleep disorders 
• nenavadne sanje, motnje spanja
Although rilpivirine demonstrated limited in vitro activity against HIV-2 with EC50 values ranging from 2,510 to 10,830 nM (920 to 3,970 ng/mL), treatment of HIV-2 infection with rilpivirine hydrochloride is not recommended in the absence of clinical data. 
Čeprav je rilpivirin in vitro pokazal omejeno aktivnost proti virusu HIV-2 z vrednostmi EC50 od 2.510 do 10.830 nM (920 do 3,970 ng/ml), se zdravljenje okužbe z virusom HIV-2 z rilpivirinijevim kloridom v odsotnosti kliničnih podatkov ne priporoča.
If serum phosphate is < 1.5 mg/dL (0.48 mmol/L) or CrCl is decreased to < 50 mL/min in any patient receiving Eviplera, renal function should be re-evaluated within one week, including measurements of blood glucose, blood potassium and urine glucose concentrations (see section 4.8, proximal tubulopathy). 
Če je vrednost serumskega fosfata < 1,5 mg/dl (0,48 mmol/l) ali se CrCl zmanjša na < 50 ml/min je pri vsakem bolniku, ki prejema zdravilo Eviplera, treba ponovno ovrednotiti ledvično funkcijo v roku enega tedna, vključno z merjenjem koncentracije glukoze in kalija v krvi ter glukoze v urinu (glejte poglavje 4.8, proksimalna tubulopatija).
It is not known whether placental transfer of rilpivirine occurs in pregnant women. 
Ni znano, ali pri nosečnicah poteka prehod rilpivirina skozi placento.